BioSig Technologies Inc Stock Price, News & Analysis

BioSig Technologies (NASDAQ: BSGM) will exhibit at Heart Rhythm 2022 from April 29 to May 1, 2022 in San Francisco. The company will showcase its PURE EP(TM) Nova-5 Software, enhancing electrophysiology with better signal fidelity. A poster presentation will highlight clinical data on Dynamic Algorithmic Notch Filtering, co-authored by noted physicians. BioSig's system, with FDA 510(k) clearance, has seen 75 physicians complete over 2,200 patient cases, demonstrating a 75% improvement in signal quality according to study results.

BioSig Technologies, Inc. (NASDAQ: BSGM) announced that CEO Kenneth L. Londoner will present at the NobleCon18 on April 20, 2022, in Hollywood, Florida. Attendees can meet BioSig management during breakout sessions. A high-definition video webcast of the presentation will be available the following day. The PURE EP™ System, an FDA-cleared device, has been used in over 2,200 cases by 75 physicians, showing a 75% improvement in intracardiac signal quality. Clinical data is published in the Journal of Cardiovascular Electrophysiology.

BioSig Technologies (Nasdaq: BSGM) announced a partnership with Summit Blue Capital to implement a leasing and finance program for its PURE EP™ System, enhancing purchase flexibility for U.S. hospitals. This collaboration aims to expedite the system's entry into new electrophysiology labs, improving commercial plans and facilitating upfront payments per installation. The FDA-cleared PURE EP™ device has successfully been used in over 2,150 patient cases. Clinical studies show a 75% improvement in signal quality compared to traditional methods.

BioSig Technologies, Inc. (Nasdaq: BSGM) has completed an underwritten public offering of 2,611,739 shares at $1.15, raising $3 million. Additionally, a cash warrant priced at $1.40 could generate another $3 million if fully exercised. The proceeds will support the commercialization of the PURE EP™ System, aimed at enhancing ECG and intra-cardiac signal fidelity. The offering was registered under Form S-3, with details available on the SEC's website.

BioSig Technologies announced a definitive purchase agreement for the sale of $3 million in common stock and warrants, led by a family office specializing in small cap emerging growth investments. The agreement involves issuing 2,611,739 shares at $1.15 each, along with warrants to purchase the same number of shares at $1.40. Proceeds will support working capital and the commercialization of the PURE EP™ System. The offering is expected to close around March 23, 2022, pending customary conditions. This funding aims to provide sufficient operating capital for the company's ongoing business plan.

BioSig Technologies has appointed John Sieckhaus as Chief Operating Officer, boosting its operational capabilities. Sieckhaus, with 30 years in healthcare, previously held senior roles at St. Jude Medical and Abbott, driving significant revenue growth. His expertise will enhance the rollout of the PURE EP™ System, which is FDA-cleared and aims to optimize cardiac electrophysiology procedures. The system has already been used in over 2150 patient cases, showing a 75% improvement in signal quality compared to conventional methods.

BioSig Technologies, Inc. (NASDAQ: BSGM) announced the allowance of a new utility patent for its PURE EP™ noise-filtering technology aimed at improving cardiac signal fidelity. This patent (17/091,357), filed on November 6, 2020, expands the company's portfolio to 49 issued or allowed patents globally. The PURE EP™ System enhances the clarity of ECG and intra-cardiac signals, crucial for treating complex arrhythmias like atrial fibrillation. This advancement underscores the platform's clinical significance, addressing a critical need in electrophysiology.

BioSig Technologies (NASDAQ: BSGM) announced that its PURE EP™ System will be highlighted at the 27th Annual International Atrial Fibrillation Symposium from January 13-15, 2022. Dr. DJ Lakkireddy will present during a Spotlight Session on January 13, showcasing clinical observations and advancements in arrhythmia care. More than 73 physicians have utilized the system in over 1800 patient cases. The company aims to expand its commercial launch in the Northeast, Texas, and Florida, with recent clinical data showing a 75% improvement in intracardiac signal quality.

BioSig Technologies concluded 2021 with over 1,800 patient cases utilizing the PURE EP™ System. The company will present at the 24th Annual Virtual Needham Growth Conference on January 14, 2022, at 4:15 PM ET. The PURE EP™ System, an FDA-cleared Class II device, enhances procedural efficiency in cardiac electrophysiology. Recent study results published in the Journal of Cardiovascular Electrophysiology confirmed a 75% improvement in signal quality. With one in 18 Americans affected by cardiac arrhythmias and increasing atrial fibrillation rates, BioSig's technology addresses a significant healthcare challenge.